肝脏MRI:如何选择合适的对比剂
本文为观点文章,讨论肝脏MRI使用的各类静脉对比剂及其理想使用方式。细胞外对比剂(ECA)可提供优良的动态期信息,用于局灶性肝脏病变定性;肝胆对比剂(HBA,尤其是钆塞酸)有助于评估具功能肝细胞的病变及胆道树,但其动态期图像不如ECA满意,尤其动脉期。选择对比剂需了解临床情况和待回答的问题。
要点
- ECA动态期图像优良,适合局灶性肝脏病变的定性评估。
- HBA(尤其钆塞酸)有助于具功能肝细胞病变的定性及胆道树评估。
- 钆塞酸动态期图像不如ECA满意,尤其动脉期。
核心结论
- 肝脏MRI对比剂选择需依据临床情况和待回答的问题,ECA与HBA各有其理想用途。
研究设计与样本
- 观点文章,讨论肝脏MRI所用各类静脉对比剂及其理想使用方式;原文未报告样本量、中心数、设备或参考标准。
临床应用与阅片要点
- 评估局灶性肝脏病变需优良动态期信息时可选用ECA。
- 需评估具功能肝细胞的病变或胆道树时可选用HBA,尤其钆塞酸。
- 使用钆塞酸时需注意其动态期图像不如ECA满意,尤其动脉期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Contrast enhanced MRI of the liver provides valuable information in the evaluation of both chronic liver disease and focal liver lesions. Currently, two classes of MRI contrast agents are available for clinical use, namely the extracellular contrast agent (ECA) and the hepatobiliary agent (HBA). The use of appropriate contrast agents for liver MRI requires knowledge of the clinical situation and question to be answered. ECAs have been used for decades since their introduction into clinical practice and provide excellent dynamic phase information that is useful in characterizing focal liver lesions. In the last decade, HBAs, particularly Gadoxetate, have been found useful for characterizing lesions with functioning hepatocytes and more importantly in evaluating the biliary tree. Gadoxetate, however, provides less satisfactory dynamic phase images compared to ECAs, particularly during the arterial phase. In this perspective article, we will discuss the various intravenous contrast agents used for liver MRI and their ideal utilization.
引用
- Welle CL, Guglielmo FF, Venkatesh SK, et al. MRI of the liver: choosing the right contrast agent. Abdom Radiol (NY). 2020. PMID: 31392396. doi:10.1007/s00261-019-02162-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。